1M7 Stock Chart & Stats
€0.35
>-€0.01(-0.57%)
At close: 4:00 PM EDT
€0.35
>-€0.01(-0.57%)
Day’s Range― - ―
52-Week Range€0.27 - €0.48
Previous CloseN/A
Volume0.00
Average Volume (3M)21.00
Market Cap
€20.81M
Enterprise Value€12.54
Total Cash (Recent Filing)€1.13M
Total Debt (Recent Filing)€873.00K
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Sep 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding54,037,327
10 Day Avg. Volume65
30 Day Avg. Volume21
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)4.06
Price to Sales (P/S)1.29
P/FCF Ratio-46.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.84Price Target Upside139.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€135.67K
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 74%–81% indicate strong unit economics from software-based cognitive tests. This margin buffer supports long-term profitability if operating costs are controlled, enables reinvestment in product R&D, and helps absorb pricing pressure in B2B contracts over months to years.
Improved Balance SheetMaterial deleveraging and stronger equity improve financial resilience and reduce refinancing risk. Lower absolute debt and a healthier equity base extend runway, increase strategic flexibility to win trials or invest in operations, and reduce interest burdens that could otherwise exacerbate losses.
B2B Licensing And Services ModelRevenue tied to licensing, trial services and data delivery creates recurring and contract-based cash flows with high client stickiness. Serving pharma/CROs and academic trials offers structural demand from ongoing clinical research, supporting predictable project pipelines and long-term client relationships.
Bears Say
Multi-year Operating LossesSustained operating and net losses over multiple years indicate the company has not yet converted its margin advantage into profitability. Persistent losses depress returns on equity, constrain reinvestment, and increase the probability of future financing needs that could dilute shareholders or limit strategic initiatives.
Declining Revenue TrendA multi-year revenue decline weakens operating leverage and suggests challenges in winning or retaining trials. Lower top-line reduces the ability to spread fixed costs, undermines margin recovery prospects, and implies the company must reverse demand or expand addressable markets to restore sustainable growth.
Negative Free Cash FlowOngoing negative free cash flow means the business remains reliant on existing cash or external funding. Although burn improved in 2025, continued negative FCF limits self-funding capacity, raising the likelihood of capital raises or constrained investment that could impair execution over the medium term.
Cambridge Cognition Holdings News
1M7 FAQ
What was Cambridge Cognition Holdings Plc’s price range in the past 12 months?
Cambridge Cognition Holdings Plc lowest stock price was €0.27 and its highest was €0.48 in the past 12 months.
What is Cambridge Cognition Holdings Plc’s market cap?
Cambridge Cognition Holdings Plc’s market cap is €20.81M.
When is Cambridge Cognition Holdings Plc’s upcoming earnings report date?
Cambridge Cognition Holdings Plc’s upcoming earnings report date is Sep 29, 2026 which is in 55 days.
How were Cambridge Cognition Holdings Plc’s earnings last quarter?
Cambridge Cognition Holdings Plc released its earnings results on Apr 13, 2026. The company reported -€0.018 earnings per share for the quarter, missing the consensus estimate of -€0.007 by -€0.011.
Is Cambridge Cognition Holdings Plc overvalued?
According to Wall Street analysts Cambridge Cognition Holdings Plc’s price is currently Undervalued.
Does Cambridge Cognition Holdings Plc pay dividends?
Cambridge Cognition Holdings Plc does not currently pay dividends.
What is Cambridge Cognition Holdings Plc’s EPS estimate?
Cambridge Cognition Holdings Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cambridge Cognition Holdings Plc have?
Cambridge Cognition Holdings Plc has 54,037,327 shares outstanding.
What happened to Cambridge Cognition Holdings Plc’s price movement after its last earnings report?
Cambridge Cognition Holdings Plc reported an EPS of -€0.018 in its last earnings report, missing expectations of -€0.007. Following the earnings report the stock price went down -0.962%.
Which hedge fund is a major shareholder of Cambridge Cognition Holdings Plc?
Currently, no hedge funds are holding shares in DE:1M7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cambridge Cognition Holdings Plc
Cambridge Cognition Holdings Plc is a neuroscience technology company focused on developing and globally marketing sophisticated cognitive testing solutions for use in clinical settings. The firm operates internationally, serving clients in the United States, United Kingdom, and European Union, among other regions. Its extensive product portfolio includes CANTAB Recruit, an online platform designed to help pharmaceutical and biotechnology companies efficiently identify and onboard eligible participants for clinical trials, particularly in high-need therapeutic areas such as Alzheimer's disease. For broader pharmaceutical research, CANTAB Connect offers digital cognitive assessment tools applicable across all clinical trial phases (I-IV) and various medical fields. Additionally, the Cognition Kit is a digital health platform that utilizes wearable and smartphone applications to collect data, aiming to boost patient involvement, validate treatment efficacy, and deepen understanding of diseases and individual responses to medication. Other specialized offerings include CANTAB Connect Research, advanced software providing precise digital metrics for cognitive function in brain research; CANTAB Mobile, a touchscreen memory test frequently used in clinical studies pertaining to Alzheimer's disease; and CANTAB BrainHealth, an online digital assessment tool for monitoring mental well-being and cognitive performance in professional environments. The company also provides CANTAB Insight, a medical device for evaluating an individual's cognitive health, and NeuroVocalix, a secure platform enabling automated administration and scoring of validated verbal cognitive assessments. Beyond its technological products, Cambridge Cognition furnishes a suite of expert consultancy and operational management services tailored to enhance clinical trials and cognitive research. These services encompass neuroscience and technical advice, study design, data analysis, comprehensive study and data management, and the provision of insightful reports and interpretations. Cambridge Cognition Holdings Plc was established in 2012 and is headquartered in Cambridge, United Kingdom.
1M7 Stock 12 Month Forecast
Average Price Target
€0.84
▲(139.97% Upside)